Michelle A. Quan
7 Papers
Michelle A. Quan is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has co-authored 6 publications.
Chat about Author
Papers
Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records
Aaron S. Rosenberg,Albert W. Riedl,Michelle A. Quan,Kwan-Keat Ang,Joseph Tuscano,Naseem Esteghamat,Brian A. Jonas,John Paul Graff,Matthew Renquist,Joseph Cawood,Jeanna L Welborn,Rasmus T. Hoeg,Paul Kaesberg,Kent Anderson,J.Y. Adams,Theresa H.M. Keegan +15 more
TL;DR: In this paper , a temporal data association platform (TDAP) was used to identify multiple myeloma patients. But, the authors only evaluated the temporal association of clinical events and the ability to assess patient trends over time.
Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Tamer Othman,Michelle A. Quan,Shiliang Zhang,Daria Gaut,Patricia A. Young,Omar Abdulmonem Mahmood,Haifaa Abdulhaq,K. S. Shieh,J. Reid,Elizabeth Brem,Nisha Hariharan,Benjamin Heyman,Joseph Tuscano +12 more
TL;DR: In this article , the authors retrospectively analyzed PCNSL adult patients who received consolidation in CR1 or underwent autoHCT during their treatment course, and the 5-year PFS from diagnosis for cohorts A vs B was 87.8% vs 37.3% (P < .001).
Investigating Differences in Treatment (Tx) Patterns and Clinical Characteristics Among Patients (Pts) Diagnosed with Multiple Myeloma (MM) Across Racial Groups
Ashley Saunders,Samantha Slaff,Krishnaveni Subbiah,T. Gu,Michelle A. Quan,Aaron S. Rosenberg +5 more
TL;DR: In this paper , the authors explored how tx patterns and clinical characteristics differ between racial groups and have evolved over a 10-y period using a large, real-world database, and found significant racial disparities in MM incidence, Tx patterns, and outcomes.
Trends in presentation, treatment, and survival in young multiple myeloma patients age 50 and under from 2000-2021.
TL;DR: In this article , the authors presented data from one of the largest retrospective cohorts of younger multiple myeloma patients, which included 209 patients with MM and 4 with plasma cell leukemia.
Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients
Michelle A. Quan,Kwan-Keat Ang,Joseph Tuscano,Mehrdad Abedi,Brian A. Jonas,Naseem Esteghamat,Jeanna L Welborn,Paul Kaesberg,Aaron S. Rosenberg +8 more
TL;DR: In this paper , the authors performed a retrospective analysis of newly diagnosed multiple myeloma (MM) patients at the age of 51 or younger to characterize this distinct population and found that those younger than age 50 represent only 5% of patients living with MM.